You can tell the fight between Allergan, Inc. (NYSE:AGN) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) is coming down to the wire. With a December proxy vote looming, both sides have fought what can only be considered a historic battle. Some of the key points in the battle are addressed in the to be unredacted confidential documents and emails primarily paint a picture of an intense battle. ValueWalk has separated the key documents into a Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and Allergan, Inc. (NYSE:AGN) camp, along with a few general observations. Questions buzzing around Ackman’s involvement in purchasing Allergan…
Most Critical Documents Supporting Allergan, Valeant
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.